Fig. 2From: Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorinPFS (A) and OS (B) according to Glasgow Prognostic Score (GPS) scoreBack to article page